Zoekresultaten - Portaal voor medische datamodellen (MDM-portaal)

Zoekresultaten filteren
Datamodellen selecteren

Geselecteerde datamodellen

U moet ingelogd zijn om meerdere datamodellen te selecteren en die te downloaden of te analyseren.

199 Zoekresultaten.

Serious Adverse Events Mepolizumab HES NCT00086658 - Serious Adverse Events

- 05-06-17 - 1 Formulier, 12 Itemgroepen, 55 Data-elementen, 1 Taal

Itemgroepen: Serious Adverse Events, Document section, Document section SAE, Document section Demography data, Document section, Document section Causations SAE, Document section Medical Conditions, Document section Risk factors, Document section Concomitant Medications, Document section, Document section, Document section

Study part: .A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Non-Serious Adverse Events Mepolizumab HES NCT00086658 - Non-Serious Adverse Events

- 05-06-17 - 1 Formulier, 1 Itemgroep, 11 Data-elementen, 1 Taal

Itemgroep: Non-Serious Adverse Events

Study part: Non-Serious Adverse Events.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Pharmacogenetic Research Mepolizumab HES NCT00086658 - PGx- Pharmacogenetic Research

- 05-06-17 - 1 Formulier, 4 Itemgroepen, 11 Data-elementen, 1 Taal

Itemgroepen: consent Pharmacogenetic Test, BLOOD SAMPLE COLLECTION, WITHDRAWAL OF CONSENT, BLOOD SAMPLE DESTRUCTION

Study part: PGx- Pharmacogenetic Research.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Mepolizumab HES NCT00086658 - Corticosteroid Medication

- 05-06-17 - 1 Formulier, 1 Itemgroep, 8 Data-elementen, 1 Taal

Itemgroep: Medication Corticosteroid

Study part: Corticosteroid Medication.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Concomitant Medication Mepolizumab HES NCT00086658 - Concomitant Medication

- 05-06-17 - 1 Formulier, 1 Itemgroep, 11 Data-elementen, 1 Taal

Itemgroep: Concomitant Medication

Study part: Concomitant Medication.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Investigational Product Discontinuation Mepolizumab HES NCT00086658 - Investigational Product Discontinuation

- 05-06-17 - 1 Formulier, 1 Itemgroep, 4 Data-elementen, 1 Taal

Itemgroep: Investigational Product Discontinuation

Study part: Investigational Product Discontinuation.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Status of treatment blind Mepolizumab HES NCT00086658 - Status of treatment blind

- 05-06-17 - 1 Formulier, 1 Itemgroep, 5 Data-elementen, 1 Taal

Itemgroep: Status of treatment blind

Study part: Status of treatment blind.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Study conclusion Mepolizumab HES NCT00086658 - Study conclusion

- 05-06-17 - 1 Formulier, 1 Itemgroep, 5 Data-elementen, 1 Taal

Itemgroep: STUDY CONCLUSION

Study part: Study conclusion.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Pregnancy Information Study Conclusion Mepolizumab HES NCT00086658 - Pregnancy Information Study Conclusion

- 05-06-17 - 1 Formulier, 1 Itemgroep, 1 Data-element, 1 Taal

Itemgroep: PREGNANCY INFORMATION

Study part: Pregnancy Information Study Conclusion.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Eligibility Criteria Day 1 Pre-Infusion Mepolizumab HES NCT00086658 - Eligibility Criteria Day 1 Pre-Infusion

- 04-06-17 - 1 Formulier, 3 Itemgroepen, 21 Data-elementen, 1 Taal

Itemgroepen: Eligibility criteria, Inclusion Criteria, Exclusion Criteria

Study part: Eligibility Criteria Day 1 Pre-Infusion.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Vital Signs Screening Visit Mepolizumab HES NCT00086658 - Vital Signs Screening Visit

- 04-06-17 - 1 Formulier, 1 Itemgroep, 9 Data-elementen, 1 Taal

Itemgroep: VITAL SIGNS

Study part: Vital Signs Screening Visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

12-Lead ECG Screening Visit Mepolizumab HES NCT00086658 - 12-Lead ECG Screening Visit

- 04-06-17 - 1 Formulier, 1 Itemgroep, 3 Data-elementen, 1 Taal

Itemgroep: 12-Lead ECG

Study part: 12-Lead ECG Screening Visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.